As 2023 began, biopharmaceutical industry observers predicted an increase in both merger-and-acquisition activity as well as the return of some larger transactions similar to the occasional mega-mergers seen before the COVID-19 pandemic. During the first quarter, this expectation was realized as Pfizer Inc. sought to bolster its cancer biologics portfolio with the $43bn acquisition of the antibody-drug conjugate specialist Seagen.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?